根據最新的財務報表(Form-10K),Nouveau Life Pharmaceuticals Inc 的總資產為 $0,淨損失為 $0
NOUV 的關鍵財務比率是什麼?
Nouveau Life Pharmaceuticals Inc 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Nouveau Life Pharmaceuticals Inc 的收入按細分市場或地理位置如何劃分?
Nouveau Life Pharmaceuticals Inc 最大收入來源為 Stereopure Oligonucleotides,在最近的收益報告中收入為 113,305,000。就地區而言,Singapore, United States, Japan, United Kingdom, and Ireland 是 Nouveau Life Pharmaceuticals Inc 的主要市場,收入為 113,305,000。
Nouveau Life Pharmaceuticals Inc 是否盈利?
無,根據最新的財務報表,Nouveau Life Pharmaceuticals Inc 的淨損失為 $0
Nouveau Life Pharmaceuticals Inc 有負債嗎?
無,Nouveau Life Pharmaceuticals Inc 的負債為 0
Nouveau Life Pharmaceuticals Inc 的流通股有多少?
Nouveau Life Pharmaceuticals Inc 的總流通股為 0
關鍵數據
前收市價
$0.0001
開盤價
$0.0001
當日範圍
$0.0001 - $0.0001
52週區間
$0 - $0.0001
交易量
--
平均成交量
579.1K
股息收益率
--
每股盈餘 (TTM)
-0.02
市值
$666.0K
什麼是 NOUV?
Nouveau Life Pharmaceuticals, Inc. engages in the provision of hardware solutions. The company is headquartered in Niverville, Manitoba and currently employs 0 full-time employees. The company went IPO on 2001-06-21. With the NOUV platform, they can monitor all of their patients at a glance. The company also provides to monitor details of each patient by just clicking on them. In the case of an emergency, NOUV will detect it before they do. The firm is also focused on its robotic and Ai-based healthcare devices and wearables. Its applications include NOUV Friends - for Seniors, NOUV Guardian - for Individual Personal Users, and NOUV Care Guardian - for Organization. Its subsidiary is Seniorgo.ai.